Self- Sampling in Cervical Cancer Routine Screening
Launched by TAMPERE UNIVERSITY HOSPITAL · Apr 9, 2025
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women that do not respond to the first national cervical cancer screening invitation in 2024 and 2025 and to whom the reminder letter is sent to.
- • Birth cohorts of women who will turn in screening year: 30, 35, 40, 45, 50, 55, 60 or 65 years old.
- Exclusion Criteria:
- • Women who do not belong to the screening year 2024 or 2025 invitation birth cohorts.
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampere, Pirkanmaa, Finland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported